Bain Capital Life Sciences

Bain Capital Life Sciences

Bain Capital Life Sciences

Xconomy

Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More

$270,000,000 Venture capital (Series C)
FinSMEs , ChinaMoneyNetwork

Freenome Closes $270M Series C Financing

Xconomy

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

$257,000,000 Venture capital (Series B)
FinSMEs

Thrive Earlier Detection Raises $257M in Series B Financing

Xconomy

On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO

neurons.AI

On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO

$150,000,000 Venture capital (Series B)
FinSMEs , Pulse 2.0

C4 Therapeutics Raises $170M in Funding

$27,000,000 Venture capital (Series D)
FinSMEs

ViaCyte Closes Approximately $27M in Series D Financing

$120,000,000 Venture capital
FinSMEs , DealStreetAsia

Rapid Micro Biosystems Raises $120M in Funding

Xconomy

Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory

Crunchbase News

Affinivax Closes On $120M Series B As Biotech Takes Center Stage Globally

$120,000,000 Venture capital (Series B)
FinSMEs

Affinivax Raises $120M in Series B Funding

Xconomy

Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials

$102,000,000 Venture capital (Series C)
FinSMEs

Kymera Therapeutics Raises $102M in Series C Financing

Xconomy , MedCity News

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

the home of AI info

Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th ...

PE HUB

SpringWorks Therapeutics debuts IPO

$75,000,000 Venture capital (Series C)
PE HUB

Annexon Biosciences takes in $75 mln Series C

$80,000,000 Venture capital (Series D)
PE HUB

ViaCyte nabs $80 mln Series D

$65,000,000 Venture capital (Series B)
PE HUB

Kymera Therapeutics attracts $65 mln Series B